Twenty-eight patients with early-stage carcinoma of the uterine cervix were treated using one standard Manchester radium application and one afterloading Selectron application. In each case, radiographs were analysed to determine differences in geometry of applicators relative to each other, or to the bony pelvis. During the Selectron treatment the applicators lay significantly more anterior in the pelvis, with a reduced angulation between the axes of the uterus and the vagina. The separation between the ovoids was increased. An identical analysis of 25 patients who had received two radium applications showed that the uterine tube lay significantly more anterior in the pelvis during the second application. Reasons for these differences and their possible clinical importance in terms of increased dose rate to critical tissue are discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1259/0007-1285-60-713-481 | DOI Listing |
Hered Cancer Clin Pract
January 2025
Division of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Carcinogenesis encompasses processes that lead to increased mutation rates, enhanced cellular division (tumour growth), and invasive growth. Colorectal cancer (CRC) carcinogenesis in carriers of pathogenic APC (path_APC) and pathogenic mismatch repair gene (path_MMR) variants is initiated by a second hit affecting the corresponding wild-type allele. In path_APC carriers, second hits result in the development of multiple adenomas, with CRC typically emerging after an additional 20 years.
View Article and Find Full Text PDFBone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend giving a bone-protecting agent (BPA) to patients with mCRPC and bone metastases. However, the data supporting these recommendations were generated before androgen receptor pathway inhibitors (ARPIs) were available.
View Article and Find Full Text PDFNat Rev Urol
November 2024
Division of Cancer Sciences, Oglesby Cancer Research Building, University of Manchester, Manchester, UK.
External beam radiotherapy is used for radical treatment of organ-confined prostate cancer and to treat lesions in metastatic disease whereas molecular radiotherapy with labelled prostate-specific membrane antigen ligands and radium-223 (Ra) is indicated for metastatic prostate cancer and has demonstrated substantial improvements in symptom control and overall survival compared with standard-of-care treatment. Prostate cancer is considered an immunologically cold tumour, so limited studies investigating the treatment-induced effects on the immune response have been completed. However, emerging data support the idea that radiotherapy induces an immune response in prostate cancer, but whether the response is an antitumour or pro-tumour response is dependent on the radiotherapy regime and is also cell-line dependent.
View Article and Find Full Text PDFAnn Surg
May 2024
Department of Colorectal Surgery and Surgical Outcomes Research Centre, Royal Prince Alfred Hospital, Sydney, Australia.
Sci Rep
May 2024
KU Leuven, Instituut voor Kern- en Stralingsfysica, Leuven, Belgium.
The presented paper discusses the production of radioactive ion beams of francium, radium, and actinium from thick uranium carbide (UC ) targets at ISOLDE, CERN. This study focuses on the release curves and extractable yields of francium, radium and actinium isotopes. The ion source temperature was varied in order to study the relative contributions of surface and laser ionization to the production of the actinium ion beams.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!